Fibroepithelial Polyp of the Renal Pelvis

Blank, Christian U.; Lissmer, L.; Kaneti, Jacob; Glikman, L.; Moroko, I.; Krugliak, L.

doi:10.1016/s0022-5347(17)44311-4

Cited by 10 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concurrent or subsequent malignancy has been observed in 15–20% of patients with inverted papillomas of the upper tract, and therefore upper tract surveillance is recommended for these patients for at least 2 years ( 35 - 37 ). Other benign lesions that can occur in the upper tract include fibroepithelial polyps and neurofibromas, which are best treated with local excision ( 38 , 39 ).…”

Section: Epidemiology and Risk Factorsmentioning

confidence: 99%

Diagnosis, workup, and risk stratification of upper tract urothelial carcinoma

Zganjar,

Thiel,

Lyon

2023

Transl Androl Urol

View full text Add to dashboard Cite

Upper tract urothelial carcinoma (UTUC) is a relatively rare disease that presents unique challenges to urologists from both a diagnostic and management standpoint. UTUC is a clinically heterogenous disease with a varied natural history, and given its location in the upper urinary tract, treatment has the potential to cause or worsen chronic kidney disease. Therefore, physicians caring for patients with UTUC must be facile with multiple diagnostic and therapeutic strategies in order to provide optimal patient care. We present an overview of the epidemiology, histology, risk factors, and contemporary approach to the diagnosis, laboratory evaluation, imaging, and risk stratification for patients with UTUC. Computerized tomographic urography, thorough endoscopic evaluation, and biopsy (endoscopically or percutaneously) remain the standard of care for the diagnosis and staging of patients with suspected UTUC. Preoperative nomograms are vital to select patients more optimally for preoperative systemic chemotherapy and facilitate clinical trial enrollment. A thorough understanding of the various diagnostic challenges, imaging/pathologic limitations, biomarkers, and risk stratification tools will allow us as a field to develop new modalities to improve our diagnostic capabilities and reduce the risk of under diagnosis and over treatment for our patients.

show abstract